Shypd.aiThe largest open index of AI toolsIktos combines generative AI, retrosynthesis, and robotics to accelerate small-molecule drug discovery. It offers platforms like Makya for AI-driven design and Spaya for efficient synthesis planning.
Trending
About
Iktos leverages cutting-edge AI and robotics to transform drug discovery, aiming to reduce timelines to under 24 months. Its platform integrates Generative AI (Makya) for de novo drug design, focusing on synthetic accessibility and multi-parametric optimization, and AI-driven retrosynthesis (Spaya) to identify feasible synthetic routes. The process is further enhanced by Iktos Robotics, which manages automated synthesis, purification, analysis, and testing, creating a fully autonomous lab environment. This integrated approach supports the entire molecular journey from inception to drug candidate, iterating through the DMTA cycle and optimizing molecular properties with multidimensional biological data.
Capabilities
Pricing & Plans
Likely Not Free
Not publicly disclosed. Check iktos.ai for current pricing.
FAQs
Trending
